Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HeLa-229 |
Human cervix adenocarcinoma cell line (derivat of HeLa) | Human | genital tract | cell line | adherent | plasmid | K2 Transfection System | publication | A. Garg et al., Blood Cells, Molecules and Diseases, 2015, 55: 248-254, doi.org/10.1016/j.bcmd.2015.07.009 | ||||
HeLa-229 |
Human cervix adenocarcinoma cell line (derivat of HeLa) | Human | genital tract | cell line | adherent | plasmid | K2 Transfection System | publication | D. Kaul et al., Blood Cells, Molecules and Diseases, 2015, 55: 89-93, doi.org/10.1016/j.bcmd.2015.05.001 | ||||
HeLa-229 |
Human cervix adenocarcinoma cell line (derivat of HeLa) | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | K2 Transfection System | publication | D. Kaul et al., Blood Cells, Molecules and Diseases, 2015, 55: 89-93, doi.org/10.1016/j.bcmd.2015.05.001 | |||
HeLa-229 |
Human cervix adenocarcinoma cell line (derivat of HeLa) | ATCC CCL-2.1 | Human | genital tract | cell line | adherent | plasmid | K2 Transfection System | application note | ![]() |
|||
HeLa-ABCA1-GFP |
Human cervix adenocarcinoma cell line (derivat of HeLa) | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | N. Mukhamedova et al., Methods Mol. Biol., 2016 ; 1354: 281-292; doi:10.1007/978-1-4939-3046-3_19 | ||||
HeLa-DR-13–9 |
Human cervix adenocarcinoma cell line (derivative of HeLa) | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | B. Haynesa et al., Biochim Biophys Acta Mol Basis Dis., 2020,1866(1): 165561, doi:10.1016/j.bbadis | Link | ||
HeLa-eGFP |
Human cervix adenocarcinoma cell line, stably expressing eGFP (derivat of HeLa) | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | P. del Pino et al., Nano Lett, Oct 2010; 10(10): 3914-21 | |||
HeLa-fLuc |
Human cervix adenocarcinoma cell line, stably expressing Firefly-Luciferase (derivat of HeLa) | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | P. del Pino et al., Nano Lett, Oct 2010; 10(10): 3914-21 | |||
HeLa-S3 |
Human cervix carcinoma cell line (subclone) | ATCC CCL-2.2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | application note | ![]() |
|||
HeLa-T4 |
Human cervix carcinoma cell line susceptible to HIV-1 infection (Derivat of HeLa ) | Human | genital tract | cell line | suspension | plasmid | Metafectene | publication | D. Wilflingseder et al., J. Immunol., Jun 2007; 178: 7840 - 7848 | Link | |||
HFFF-tet |
Human fetal foreskin fibroblasts (hTERT-immortalized expressing the tetracycline repressor) | Human | genital tract | cell line | adherent | bacmid | virusproduction | K2 Transfection System | publication | K. Laib Sampaio et al., Journal of General Virology, 2016, 97: 1917-1927, DOI 10.1099/jgv.0.000475 | Link | ||
HFFFtet |
Human fetal foreskin fibroblasts (hTERT-immortalized expressing the tetracycline repressor) | Human | genital tract | cell line | adherent | bacmid | K2 Transfection System | publication | N. Weiler et al., Viruses, 2021, 13: 614, doi.org/10.3390/v13040614 | Link | |||
HOSE |
Human non-tumorigenic, immortalized ovarian epithelial cells | Human | genital tract | cell line | adherent | plasmid | Metafectene | application note | ![]() |
||||
KGN |
Human ovary granulosa-like tumor cell line | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | L. Bouazzi et al., J. Gyneco.l Reprod. Med., 2018, 2(1):1-9 | Link | |||
KGN |
Human ovary granulosa-like tumor cell line | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | T. Sugawara et al., J. Biol. Chem., Oct 2003; 278: 42487 - 42494 | Link | ||
KGN |
Human ovary granulosa-like tumor cell line | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. Lang-Muritano et al., J. of Clinical Endocrinology & Metabolism, 2018, 103(10): 3748–3756 | ||||
KGN |
Human ovary granulosa-like tumor cell line | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | L. Bouazzi et al., Scientific Reports, 2019, 9: 17033, doi.org/10.1038/s41598-019-53370-4 | Link | |||
KGN |
Human ovary granulosa-like tumor cell line | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | D. Fu et al., Endocr. Relat. Cancer, Mar 2014; 21: 297 - 310 | Link | ||
KGN |
Human ovary granulosa-like tumor cell line | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | C. Wang et al., Am. .J Transl. Res., 2012, 4 (4): 390-402 | Link | ||
Lec1 |
Chinese hamster ovary cell line | ATCC CRL-1735 | Hamster | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene | publication | A. Altamirano et al., J. Proteome Res., 2018, 17: 1269−1277, DOI:10.1021/acs.jproteome.7b00867 | ||
Lec2 |
Chinese hamster ovary cell line (derivat of CHO) | ATTC CRL 1736 | Hamster | genital tract | cell line | adherent | plasmid | Metafectene | publication | R. Kabuß et al., Glycobiology, Oct 2005; 15: 905 - 911 | Link | ||
Lec8 |
Chinese hamster ovary cell line (derivat of CHO) | ATCC CRL 1737 | Hamster | genital tract | cell line | adherent | plasmid | Metafectene | publication | R. Kabuß et al., Glycobiology, Oct 2005; 15: 905 - 911 | Link | ||
LNCaP |
Human prostate carcinoma cell line | ATCC CRL-1740 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | M. Endres et al., Oncotarget, 2016, 7(39): 64244-64259 | Link | |
LNCaP |
Human prostate carcinoma cell line | ATCC CRL-1740 | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | U. K. Mukhopadhyay et al., Cancer Res., Apr 2005; 65: 2872 - 2881 | Link | |
LNCaP |
Human prostate carcinoma cell line | ATCC CRL-1740 | Human | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene PRO | publication | J. Elvenes et al., PLoS ONE, 2011, 6(9): e24659, doi:10.1371/journal.pone.0024659 | Link |